Risk factors and long-term outcomes of pediatric liver transplant recipients with chronic high Epstein-Barr virus loads
- PMID: 29677384
- DOI: 10.1111/tid.12911
Risk factors and long-term outcomes of pediatric liver transplant recipients with chronic high Epstein-Barr virus loads
Abstract
Background: Serial monitoring of Epstein-Barr virus (EBV) reveals that certain pediatric liver transplant (LT) recipients exhibit high EBV loads for long periods. We investigated the incidence and risk factors of chronic high EBV (CHEBV) loads (continuous EBV DNA >10 000 IU/mL of whole blood for ≥6 months) and long-term outcomes.
Methods: This single center, retrospective observational study investigated pediatric LT recipients who survived ≥6 months. We quantitated EBV DNA weekly during hospitalization and subsequently every 4 or 6 weeks at the outpatient clinic. Tacrolimus was maintained at a low trough level (<3 ng/mL, EBV DNA load >5000 IU/mL).
Results: Thirty-one of 77 LT recipients developed CHEBV. Univariate analysis revealed that age <2 years and body weight <10 kg upon LT, operation time <700 minutes, warm ischemia time (WIT) >35 minutes, graft-to-recipient weight ratio (GRWR) >2.7%, and preoperative EBV seronegativity were significantly associated with the development of CHEBV loads. Multivariate analysis identified significant associations of CHEBV with WIT >35 minutes, GRWR >2.7%, and preoperative seronegative. None of the recipients developed post-transplantation lymphoproliferative disorder. Survival rates of patients with and without CHEBV loads were not significantly different.
Conclusions: A significant number of pediatric LT recipients developed CHEBV loads. Long WIT, high GRWR, and preoperative EBV seronegativity were significantly associated with the development of CHEBV loads. Although the long-term outcomes of patients with or without CHEBV loads were not significantly different, further studies of more subjects are warranted.
Keywords: Epstein-Barr virus; long-term outcome; pediatric liver transplantation; post-transplant lymphoproliferative disorder; risk factors.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
-
The impact of chronic Epstein-Barr virus infection on the liver graft of pediatric liver transplant recipients: A retrospective observational study.Transpl Infect Dis. 2021 Oct;23(5):e13731. doi: 10.1111/tid.13731. Epub 2021 Sep 22. Transpl Infect Dis. 2021. PMID: 34500501
-
Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation.J Formos Med Assoc. 2019 Sep;118(9):1362-1368. doi: 10.1016/j.jfma.2018.12.007. Epub 2019 Jan 3. J Formos Med Assoc. 2019. PMID: 30612881
-
Low-dose immunosuppression reduces the incidence of post-transplant lymphoproliferative disease in pediatric liver graft recipients.J Pediatr Gastroenterol Nutr. 2004 Feb;38(2):198-203. doi: 10.1097/00005176-200402000-00018. J Pediatr Gastroenterol Nutr. 2004. PMID: 14734884
-
Epstein-Barr virus associated smooth muscle tumors in solid organ transplant recipients: Incidence over 31 years at a single institution and review of the literature.Transpl Infect Dis. 2019 Feb;21(1):e13010. doi: 10.1111/tid.13010. Epub 2018 Oct 25. Transpl Infect Dis. 2019. PMID: 30298678 Review.
-
[Diffuse lymphoproliferative disease after renal transplantation and its relation with Epstein-Barr virus. Experience at one center].Nefrologia. 2002;22(5):463-9. Nefrologia. 2002. PMID: 12497748 Review. Spanish.
Cited by
-
Chronic Epstein-Barr viral load carriage after pediatric organ transplantation.Front Pediatr. 2024 Jan 31;12:1335496. doi: 10.3389/fped.2024.1335496. eCollection 2024. Front Pediatr. 2024. PMID: 38357509 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical